Maternal vitamin status contributes to clinical spontaneous abortion, but the role of B-vitamin and homocysteine status in subclinical early pregnancy loss is unknown. Three-hundred sixty-four textile workers from Anqing, China, who conceived at least once during prospective observation (1996)(1997)(1998), provided daily urine specimens for up to 1 year, and urinary human chorionic gonadatropin was assayed to detect conception and early pregnancy loss. Homocysteine, folate, and vitamins B 6 and B 12 were measured in preconception plasma. Relative to women in the lowest quartile of vitamin B 6 , those in the third and fourth quartiles had higher adjusted proportional hazard ratios of conception (hazard ratio (HR) ¼ 2.2, 95% confidence interval (CI): 1.3, 3.4; HR ¼ 1.6, 95% CI: 1.1, 2.3, respectively), and the adjusted odds ratio for early pregnancy loss in conceptive cycles was lower in the fourth quartile (odds ratio ¼ 0.5, 95% CI: 0.3, 1.0). Women with sufficient vitamin B 6 had a higher adjusted hazard ratio of conception (HR ¼ 1.4, 95% CI: 1.1, 1.9) and a lower adjusted odds ratio of early pregnancy loss in conceptive cycles (odds ratio ¼ 0.7, 95% CI: 0.4, 1.1) than did women with vitamin B 6 deficiency. Poor vitamin B 6 status appears to decrease the probability of conception and to contribute to the risk of early pregnancy loss in this population.
associated with increased risk of clinical spontaneous abortion (9, 13, 14) .
In addition to losses that occur after a pregnancy is clinically recognized, as many as two thirds of losses occur before a woman knows she is pregnant (15, 16) . However, no studies to date have examined the role of nutritional status in early pregnancy loss. In the current study, we assessed the associations between preconception B-vitamin and homocysteine status and the risks of conception, early pregnancy loss, and clinical pregnancy in a prospective cohort of young Chinese women. To accurately measure conception and early pregnancy loss, we assayed human chorionic gonadotropin (hCG) in daily urine samples collected from the time a woman stopped using contraception until she became pregnant. We assayed vitamin biomarkers in plasma samples collected at baseline, before women stopped using contraception, to assess micronutrient status during the period when they were attempting to conceive.
MATERIALS AND METHODS

Study population
This study is part of a large prospective study of reproductive health conducted from 1996 to 1998 in textile mills in Anhui, China. The study protocols were approved by the human subjects committees of the affiliated Chinese institutions and by the Institutional Review Board of the Harvard School of Public Health, and all women provided written informed consent.
A detailed description of the study population and data collection methods has been reported previously (16) . Briefly, the eligibility criteria for women were as follows: 1) fulltime employment; 2) aged 20ÿ34 years; 3) newly married; and 4) had obtained permission to have a child. All the women were nulliparous. Women were excluded if they were already pregnant before enrollment, had tried unsuccessfully to get pregnant for 1 year or more at any time in the past, or planned to quit/change jobs or move out of the city over the 1-year course of follow-up. None of the women had medical conditions that predisposed them to early pregnancy loss, and the rates of fertility and pregnancy losses in our study population were similar to those in previous studies (15) (16) (17) .
Of 1,006 newly married women who were screened (more than 90 percent of newly married women employed at the mill), 961 met the eligibility requirements and agreed to enroll. We excluded 386 enrolled women from this analysis because they did not collect daily urine (n ¼ 121), did not begin collecting urine soon after stopping contraception (n ¼ 53), never stopped using contraception (n ¼ 95), became pregnant due to contraceptive failure (n ¼ 78), were lost to follow-up (n ¼ 8), withdrew shortly after enrollment (n ¼ 27), or had inadequate diary data (n ¼ 4). The 386 women excluded for the previous reasons were similar to the remaining enrolled women (16) . Of the remaining 575 women, 193 were excluded because they did not have baseline nutritional biomarker data, three because they reported current smoking or alcohol use, and 15 because they never conceived and so were not at risk for pregnancy losses. The current analysis is based on 1,165 menstrual cycles from the remaining 364 women after exclusion of 99 cycles in which there was no intercourse reported in a daily diary. Compared with the 364 women included in this analysis, the 211 women excluded because of missing data on nutrition, smoking, alcohol, or failure to conceive were similar in terms of age, height, weight, and body mass index (weight (kg)/height (m) 2 ) but were more educated (45 percent with a high school education or beyond vs. 30 percent).
Data collection procedures
Women's height and body weight in light clothing were measured to the nearest 0.1 cm and 0.1 kg, respectively. An interviewer administered a baseline questionnaire that collected historical data on reproductive history, sociodemographic characteristics, alcohol use, and environmental and occupational exposures. A follow-up questionnaire was administered trimonthly for women who had not become pregnant and at the end of the first, second, and third trimesters of pregnancy for women who became pregnant. If a woman reported a missed or late period or had early signs/symptoms of pregnancy, she was instructed to have a check-up at the affiliated hospital and to provide a urine sample for hCG assay. Once pregnancy was confirmed, the woman received regular prenatal care, delivery services, and postnatal care and was followed up by staff at the designated hospitals according to standard clinical guidelines.
Beginning with the date that contraceptive use ended, each woman kept a daily diary to record sexual intercourse, vaginal bleeding, medication, and medical conditions. She also collected a daily morning first-urine specimen for hCG assay. Daily diary information and urine specimens were collected for up to 12 months or until a pregnancy was clinically confirmed. The first of two consecutive days of bleeding reported in the daily diary was defined as the first day of a menstrual cycle. Women were monitored during ensuing pregnancies (or up to 1 year after beginning to attempt pregnancy if no pregnancy occurred), and all pregnancy outcomes were recorded.
Major outcomes and method of evaluation
The outcomes in this study were defined as follows.
1. Conception: a conception detected by urinary hCG assay.
To distinguish normal variation from a true hCG rise due to conception and to address missing hCG values, we used Bayesian methods (18, 19) to model daily conception status among all the female subjects, including female controls who were not at risk of conception. We showed that this model was 100 percent sensitive and specific for those cycles in which the conception status was observable; that is, the probability of conception was 0.0 in all control cycles and 1.0 in all cycles with conception leading to clinical pregnancy (refer to ''Laboratory assay of urinary hCG'') (16). 2. Clinical pregnancy: any pregnancy that lasted 6 weeks (42 days) or more after the onset of the last menstrual period and was confirmed by hCG assay.
3. Early pregnancy loss: pregnancy loss detected by urinary hCG assay (refer to definition of conception above) occurring less than 6 weeks (42 days) after the onset of the last menstrual period.
Nutritional analyses
At the time of the initial interview, nonfasting blood samples were collected via venipuncture into 10-ml ethylenediaminetetraacetic acid-treated tubes. The blood was centrifuged, and plasma was obtained and stored at ÿ20°C until shipped on dry ice to the Harvard School of Public Health, where it was stored at ÿ70°C prior to nutritional analyses. Frozen samples were then transported to the Jean Mayer USDA [US Department of Agriculture] Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, where plasma concentrations of homocysteine, folate, and vitamins B 6 and B 12 were measured. The total homocysteine concentration in plasma was determined by use of a method described by Araki and Sako (20) . Plasma folate and vitamin B 12 were determined by radioimmunoassay using a commercially available kit from the BioRad Diagnostics Group (Hercules, California). Plasma vitamin B 6 (as pyridoxal 5#-phosphate (PLP)) was measured by the tyrosine decarboxylase apoenzyme method (21) .
Plasma vitamin concentrations were compared with published reference values to determine the proportions of women with biochemical evidence of vitamin deficiency, defined as less than 6.8 nmol/liter (3 ng/ml) for folate (22) , less than 30 nmol/liter of PLP for vitamin B 6 (23) , and less than 258 pmol/liter (350 pg/ml) for vitamin B 12 (24, 25) . There is no standard definition of elevated homocysteine. For these analyses, we defined elevated homocysteine as a plasma concentration of 12.4 lmol/liter or greater, which is consistent with the cutoff used in a previous analysis in this cohort (22) .
Laboratory assay of urinary hCG
Urine specimens were stored at ÿ20°C. Urinary hCG levels were analyzed per batch by the immunoradiometric assay developed by O'Connor et al. (26) using a combination of capture antibodies for the hCG free b subunit and hCG b core fragment (i.e., B204) and the intact hCG molecule (i.e., B109). This assay is highly sensitive and specific. The lowest hCG concentration detectable by the assay was 0.01 ng per ml (1 mIU ¼ 0.2 ng). The cross-reaction of the assay with either intact luteinizing hormone or the luteinizing hormone-free b subunit was less than 1 percent. All urine specimens from each woman were analyzed and tested during a single run of the assay. Each urine specimen during the window from ÿ10 to þ5 days of a menstrual cycle was assayed in duplicate. Discrepancies of more than threefold between duplicate assays were presumed to result from technical error, and the assay was repeated. For the remainder, the geometric mean of the replicates was used to summarize the results for each sample. Urinary creatinine was measured by the Jaffe reaction described by Husdan and Rapoport (27) . All hCG values were normalized to creatinine values to adjust for urine concentration. For reference values, we determined levels of hCG from 67 nonconception cycles of 37 control women who were married but using contraception (n ¼ 4), not married (n ¼ 23), or married but not cohabitating with their husbands (n ¼ 10) (16).
Statistical analysis
We described important epidemiologic characteristics of subjects using means and frequencies. We then grouped plasma concentrations of homocysteine and each B vitamin (B 6 , B 12 , and folate) in two ways: 1) ordinal quartiles of equal sample sizes and 2) binary categories of normal and abnormal (refer to definitions of elevated homocysteine and deficient B vitamins in ''Nutritional analyses''). We used Cox proportional hazards methods (28) to estimate the hazards of conception and clinical pregnancy 1) in the upper three quartiles of homocysteine and B vitamins relative to the lowest quartile and 2) in normal relative to abnormal binary categories (B vitamins) or abnormal relative to normal binary categories (homocysteine). Because we prospectively observed study women for up to 1 year until they achieved a clinical pregnancy, women who had early pregnancy losses prior to clinical pregnancy remained in our cohort and might have had more than one observed conception. We considered the cycles after early pregnancy losses to be the first cycles of new attempted conceptions. We used robust variance estimates (29) to accommodate nonindependence of hazards in multiple attempted conceptions from the same woman. Parameter estimates were similar when we modeled all attempted conceptions versus only the first observed conception from each woman. There were nine rightcensored attempted conceptions in which conception did not occur before the end of follow-up and 17 right-censored clinical pregnancy attempts. Each woman had a maximum of one observed clinical pregnancy, and the time to clinical pregnancy was calculated from the beginning of the first conception attempt. We presented these models with and without adjustment for woman's age, body mass index, history of pregnancy, self-reported stress, working shifts, occupational noise and dust exposures, education, and husband's age, smoking, and alcohol drinking. In addition, adjusted models for each B vitamin included the other two remaining B vitamins.
We next limited our analysis to conception cycles and used logistic regression to investigate the relative odds of early pregnancy losses using the same quartile and binary plasma concentration categories as above for homocysteine and B vitamins. We first examined early pregnancy losses by use of only the first observed conception. We then repeated the analyses using all observed conceptions and estimated standard errors using generalized estimating equations to accommodate correlations in pregnancy losses among conceptions from the same women (30) . Each model was analyzed with and without adjustment for the same covariates as used in the proportional hazards models.
RESULTS
This report includes 364 women who conceived at least once during prospective observation, had adequate daily diary and hCG data, and for whom preconception vitamin and homocysteine concentrations were available (table 1) . This was a young, generally lean cohort of newly married women who had obtained permission to have a baby. Most women had no more than a middle-school education, and nearly all worked rotating shifts. Only about 2 percent of women reported using vitamin supplements of any kind. Although women in this group did not smoke or drink alcohol, 57 percent were exposed to passive smoking, and 42 percent reported moderate to high life stress. Overall, 486 (42 percent) of 1,165 cycles resulted in conception; 139 (29 percent) of the 486 conceptions ended in early pregnancy loss.
In general, B-vitamin deficiencies were common in this cohort. Plasma concentrations of PLP indicative of vitamin B 6 deficiency were detected in 23 percent of the women, folate deficiency was observed in 20 percent, 18 percent had biochemical evidence of vitamin B 12 deficiency, and 10 percent had elevated homocysteine. Overall, 43 percent of the women were deficient in at least one vitamin, although just 9 percent were deficient in both folate and vitamin B 6 , 7 percent were deficient in both vitamins B 6 and B 12 , and 5 percent were deficient in folate and vitamin B 12 . Only 3 percent of women were deficient in all three vitamins. The total homocysteine concentration was significantly inversely correlated with both folate (r ¼ ÿ0.17; p ¼ 0.001) and vitamin B 12 (r ¼ ÿ0.14; p ¼ 0.009) and positively correlated with vitamin B 6 (r ¼ 0.17; p ¼ 0.001). Significant positive correlations (r ¼ 0.22-0.29; p < 0.001) also were observed among the three vitamins. Table 2 shows the relative hazards of conception for women within different plasma concentrations of B vitamins and homocysteine. Relative to women in the first quartile of plasma vitamin B 6 , the relative hazards of conception were higher for women in the third (adjusted hazard ratio (HR) ¼ 2.2, 95 percent confidence interval (CI): 1.3, 3.4) and fourth (adjusted HR ¼ 1.6, 95 percent CI: 1.1, 2.3) quartiles. Women with a normal concentration of plasma vitamin B 6 had a higher hazard of conception (adjusted HR ¼ 1.4, 95 percent CI: 1.1, 1.9) than did those with vitamin B 6 deficiency.
We assessed the relative odds of early pregnancy loss in conception cycles of women within different plasma concentrations of B vitamins and homocysteine (table 3) We were unable to assess whether specific combinations of B-vitamin deficiencies were associated with conception, early pregnancy loss, or clinical pregnancy because of our limited sample size. However, we did assess whether multiple deficiencies in general were associated with these outcomes. Being deficient in any one or two vitamins was not significantly associated with conception, early pregnancy loss, or clinical pregnancy. However, compared with women who were not deficient in any of the three vitamins, women who were deficient in all three vitamins (n ¼ 10) had * Includes nine right-censored conception attempts in which conception did not occur before the end of follow-up. y Models adjusted for woman's age, body mass index, history of pregnancy, self-reported stress, working shifts, occupational noise and dust exposures, education, and husband's age, smoking, and alcohol drinking. Models for vitamin B 6 , vitamin B 12 , and folate adjusted for each of the other vitamins. Standard errors for both crude and adjusted models were estimated to accommodate correlations in hazards of multiple conceptions from the same woman.
adjusted hazard ratios for conception of 0.3 (95 percent CI: 0.2, 0.5) and for clinical pregnancy of 0.2 (95 percent CI: 0.1, 0.6). We did not have sufficient statistical power to test the odds of early pregnancy loss in those with three vitamin deficiencies relative to those with none.
DISCUSSION
Our study examined the relations between preconception B-vitamin status and conception, early pregnancy loss, and clinical pregnancy in a prospective cohort of young Chinese * All models adjusted for woman's age, body mass index, history of pregnancy, self-reported stress, working shifts, occupational noise and dust exposures, education, and husband's smoking. Models for vitamin B 6 , vitamin B 12 , and folate adjusted for each of the other vitamins. Estimated parameters were similar in unadjusted models (not shown).
y Standard errors were estimated to accommodate correlations in pregnancy losses among conceptions from the same woman.
women who were attempting to become pregnant. We found that higher preconception plasma vitamin B 6 concentrations were associated with reduced odds of early pregnancy losses and higher probabilities of achieving conception and clinical pregnancy. In a previous report based on women from this same cohort, we reported that the mean prepregnancy plasma vitamin B 6 concentration was significantly lower in women whose pregnancies ended in a clinically recognized spontaneous abortion than in those with livebirths (11) . women with placental abruption or infarction compared with control women. Taken in their entirety, these observations suggest that maternal vitamin B 6 status may influence reproductive events throughout the entire course of pregnancy, from the time of conception through delivery.
The physiology underlying the relation between low vitamin B 6 status and early pregnancy loss is unknown, although several biologically plausible mechanisms are possible. Vitamin B 6 -dependent coenzymes participate in over 100 reactions involved in the metabolism of amino acids, lipids, nucleic acids, and glycogen (31) . Vitamin B 6 deficiency has also been associated with impairment of enzymes involved in the structural integrity of arterial walls (32) , which could affect implantation and early placental development. Low maternal prepregnancy vitamin B 6 status could influence early gestational events through these well-known functional roles of the vitamin. In addition, numerous studies have documented associations between low vitamin B 6 status and inflammatory responses (33) (34) (35) (36) , and inflammation has been linked to early pregnancy loss (37, 38) . Although we did not assess biomarkers of inflammation in our study, previous studies in Chinese textile workers have shown that exposure to cotton dust initiates both acute and chronic lung inflammation (39) . Work-related inflammatory exposures coupled with low vitamin B 6 status may have affected the risk of early pregnancy loss in the female textile workers in our cohort. The potential relation between vitamin B 6 and inflammation might also help to explain our unexpected positive correlation between plasma concentrations of vitamin B 6 and homocysteine, since vitamin B 6 levels appear to be lower in inflammatory states independent of homocysteine levels (34) . Additional studies that include an independent marker of inflammation, such as C-reactive protein (34), will be needed, however, to help clarify a potential interrelation among vitamin B 6 status, inflammation, and early pregnancy loss.
A strength of the current study was that we collected consecutive daily urine samples throughout the entire study period, which allowed us to assay hCG and accurately detect conception and early pregnancy losses. We also assessed vitamin status using plasma samples collected prior to when women began attempting to become pregnant. A limitation was that we based micronutrient status assessment on a single blood sample taken at enrollment. Because some women continued to use contraception after enrolling, some pregnancy outcomes occurred quite distal to micronutrient status assessment. It is possible, therefore, that the women's nutritional status changed between assessment and pregnancy outcome, leading to potential misclassification. For example, although vitamin supplement use in this rural area of China was very low, health-conscious women still might have been more likely to begin vitamin supplementation when they stopped contraception. Misclassification of micronutrient status might explain why the association of vitamin B 6 with the hazard of conception appeared to be nonlinear. Another limitation was that, out of 961 enrolled women, we excluded 597 from this analysis. Compared with the excluded women, those included had similar age, height, weight, and body mass index, but less education. Thus, our sample might not be representative of the entire enrolled cohort.
In conclusion, we found that poor preconception vitamin B 6 status was associated with increased risk of early pregnancy loss and reduced probabilities of conception and clinical pregnancy in a prospective cohort of young Chinese women. This study underscores the potential importance of micronutrient status at the time of conception on pregnancy outcome.
